Clinical Trial Spotlight: Should a Third Generation EGFR Inhibitor be First Line Therapy for EGFR Mutation-Positive NSCLC?

GRACE Videos and Articles

Dr. Jack West introduces the question of whether third generation EGFR tyrosine kinase inhibitors osimertinib and rociletinib should be used as first line therapy rather than for acquired resistance, including discussing key clinical trials on the topic.

Get more information about the FLAURA Trial and TIGER-1 Trial.

EGFR Tyrosine Kinase Inhibitors in Advanced BAC

Are EGFR Inhibitors Only Useful in Certain Patient Groups?

Is Rash a Good Thing with EGFR Inhibitors?

Management Approaches for EGFR Inhibitor-Induced Rash

Timing EGFR Inhibitors and Chemo: Why I Don't Give Them Concurrently

EGFR Monoclonal Antibody Therapy in NSCLC: A Focus on Erbitux

EGFR Inhibitor Therapy as Maintenance Therapy in Stage III NSCLC: A Cautionary Tale

Direct Comparison of EGFR Inhibitor Therapy vs. Chemo in Previously Treated NSCLC Patients

EGFR Inhibitors Iressa and Tarceva: A Tale of Two TKIs (Part I)